

PLENARY SESSIONS	PARALLEL SESSIONS	NETWORKING EVENT	ACADEMY
INDUSTRY SUPPORTED SESSION Not Included in the Main Event CME / CPD Credit	PRE-CONGRESS COURSES		

14th International Congress on Autoimmunity Program

Friday, 17 May 2024

	HALL A	HALL B	HALL C
09:00 - 12:00		PRE-CONGRESS WORKSHOP Imaging in autoimmune rheumatic diseases Iris Eshed, Israel, Gideon Flusser, Israel	PRE-CONGRESS WORKSHOP Ultrasound in autoimmune rheumatic diseases Carlo Perricone, Italy, Alexandra Balbir-Gurman, Israel, Alojzija Hocevar, Slovenia
12:15 - 17:15			ACADEMY OF AUTOIMMUNITY Autoimmunity an up-to date 1. Autoimmunity vs autoinflammation: same or different? Zoltán Szekanecz, Hungary 2. Regulatory T cells and Autoimmunity. Mitesh Dwivedi, India 3. The significance of cytokines in autoimmune diseases. Dimitrios Bogdanos, Greece SHORT BREAK 13:45 - 14:00 4. Primary biliary cholangitis (PBC)-a classical autoimmune disease. Zsigmond Ehud, Israel 5. Thyroid autoimmunity in other autoimmune diseases. Alessandro Antonelli, Italy SHORT BREAK 15:00 - 15:15 6. Comorbidities in autoimmune diseases - state of the art. Lessons learnt from big data analyses. Amital Howard, Israel 7. IVIG as pancea in autoimmune diseases. Maria Giovanna Danieli, Italy
17:15-17:45	SHORT BREAK		
17:45-19:30	OPENING CEREMONY & WELCOME RECEPTION Ceremony of Lifetime Contribution to Autoimmunity Awards		

Saturday, 18 May 2024

	HALL A	HALL B	HALL C
08:00 – 10:00	<p>PLENARY 1 Chairs: Tadej Avcin, Slovenia, Andrea Doria, Italy, Howard Amital, Israel 1. Uveitis in autoimmune diseases - why the uvea is so prevalently involved. Vicktoria Vishnevskia-Dai, Israel 2. What's still unresolved in Hughes Syndrome /Anti phospholipid syndrome. Graham Hughes, UK 3. Genetic predisposition to autoimmunity and autoinflammation. Bodo Grimbacher, Germany ----- Challenge the Expert Chairs: Yehuda Shoenfeld, Israel, Christopher Edwards, UK Experts: Iris Eshed, Israel 1. CT vs. MRI. Who needs CT when there is MRI? Is there a future for CT imaging? 2. Diffuse idiopathic skeletal hyperostosis, is it an inflammatory disease? 3. Is there a difference between SAPHO (sacroiliitis, Acne Pustulosis, Hyperostosis, Osteitis) and CRMO (chronic relapsing multifocal osteomyelitis)? Dennis McGonagle, UK 1. Why doesn't Interleukin-23 blockade work in Ankylosing Spondylitis 2. What is the difference between Ankylosing Spondylitis and axial Psoriatic Arthritis in terms of pathogenesis 3. Will Faecal microbial transplants revolution Spondyloarthritis and prevention?</p>		
10:00 – 10:30	<p>COFFEE BREAK, EXHIBITION, POSTER VIEWING New Book signing session 1 (10:05-10:25, Exhibition area) 'Autoimmunity, COVID-19, Post-COVID19 Syndrome and COVID-19 Vaccination' Participants: Yehuda Shoenfeld, Arad Dotan</p>		
10:30 – 12:00	<p>PS01 APS: What's new in antiphospholipid syndrome? Chairs: Graham Hughes, UK; Maria Tektonidou, Greece; Sonja Praprotnik, Slovenia 1. New classification criteria for the antiphospholipid syndrome. Ricard Cervera, Spain 2. Cardiovascular risk prevention and management in antiphospholipid syndrome. Maria Tektonidou 3. Time to treat to target in APS. Savino Sciascia, Italy 4. Challenges in pediatric antiphospholipid syndrome. Tadej Avcin, Slovenia 5. Implementation of the new ACR/EULAR classification criteria for antiphospholipid syndrome in clinical practice. Saša Čučnik, Slovenia</p>	<p>PS02 COVID-19, Post COVID Syndrome and Autoimmunity Chairs: Carmen Scheibenbogen, Germany; Natalia Gavrilova, Russia; Zaiga Nora-Krūkle, Latvia 1. Myositis in the COVID-19 Era-Mere coincidence. Dennis McGonagle, UK 2. COVID-19, Post COVID syndrome, "ME/CFS" Vaccines and Autoimmune Adverse Effects. Carmen Scheibenbogen, Germany 3. Severity of neurological long-COVID symptoms correlates with increased level of autoantibodies targeting vasoregulatory and autonomic nervous system receptors - single center experience. Nina Babel, Germany 4. New Onset Autoimmune Diseases after the Sputnik Vaccine. Olga Vera-Lastra, Mexico 5. IVIG as a treatment option for the post-COVID-19 condition. Personal experience. Natalia Gavrilova, Russia</p>	<p>PS03 Chimeric antigen receptor (CAR) T-cell and novel therapies in autoimmune diseases Chairs: Sylviane Muller, France; Luis E. Andrade, Brazil; Laurent Arnaud, France Session dedicated in memory of Prof. Alan Wiik 1. Use of CART-T cells in systemic lupus erythematosus. Dominique Farge, France 2. Cell therapy approaches for autoimmune diseases. Luis E. Andrade, Brazil 3. Novel Therapy Cannabis in Autoimmunity. Howard Amital, Israel 4. How therapeutic peptides work in autoimmune diseases: P140 peptide corrects failures in secondary lymphoid organs with an impact on remote tissues. Sylviane Muller, France 5. Glycan as new immunomodulatory targets in SAIDs. António Marinho, Portugal 6. Predicting treatment response according to RNA gene expression in systemic sclerosis, from bench to bedside. Doron Rimar, Israel</p>
12:00 – 14:00	<p>LUNCH BREAK, EXHIBITION, E-POSTER DISCUSSIONS, E-POSTER VIEWING (EXHIBITION AREA)</p>		
	<p>INDUSTRY SUPPORTED SESSION 12:15 - 13:45 NOT INCLUDED IN THE MAIN EVENT CME/CPD CREDIT</p>	<p>INDUSTRY SUPPORTED SESSION 12:15 - 13:45 NOT INCLUDED IN THE MAIN EVENT CME/CPD CREDIT</p>	
14:00 – 15:30	<p>PS04 LUPUS - 2025 Chairs: Mentago Li, China; Luís Inês, Portugal; Mariele Gatto, Italy 1. Belimumab vs. Anifrolumab in SLE: which drug in which patient? Andrea Doria, Italy 2. Challenges of systemic lupus erythematosus associated pulmonary arterial hypertension. Mentago Li, China 3. Flares in SLE: How to predict and measure in daily clinical practice? Luís Inês, Portugal 4. Immune complex analyses in systemic lupus erythematosus. Johan Rönnelid, Sweden 5. New strategies to achieve remission in SLE. Claudio Galarza-Maldonado, Ecuador</p>	<p>PS05 Pregnancy and Autoimmunity Chairs: Angela Tincani, Italy; Natasa Toplak, Slovenia; Caterina De Carolis, Italy 1. The joints in the pregnant lady. Iris Eshed, Israel 15 min 2. Pregnancy and rare systemic autoimmune diseases. Marta Mosca, Italy 15 min 3. Gender medicine in autoimmunity: from bench to bedside and more. Roberta Gualtierotti, Italy 4. Thyroid, autoimmune diseases, recurrent spontaneous abortion and RAFS. Caterina De Carolis, Italy</p>	<p>PS06 Systemic Sclerosis, Psoriasis and Spondyloarthritis Chairs: Abdulla Watad, Israel; Dennis McGonagle, UK; Alexandra Balbir, Israel 1. Systemic sclerosis: from pathophysiology to novel therapeutic approaches. Katja Lakota, Slovenia 2. Natural history of systemic sclerosis: a 15-years single-center experience. Dimitrios Bogdanos, Greece 3. Connective tissue diseases associated PAH. Luc Mouthon, France 4. Complete resolution of gastric antral vascular ectasia in systemic sclerosis after autologous stem cell transplantation - a case series with long term results. Doron Rimar, Israel</p>
15:30 – 15:45	<p>SHORT BREAK</p>		

15:45 – 16:45	<p>PS07 Mechanisms in Autoimmunity (Part 1) Session dedicated in memory of Prof. Noel Rose Chairs: George Wick, Austria; Ferdinando Nicoletti, Italy; Dimitrios Bogdanos, Greece 1. Educating Medical Students to Think Autoimmunity. Arnon Afek, Israel 2. Triggering of Autoimmunity by Mechanical Stress. George Wick, Austria 3. Galectins in autoimmune diseases friends or foes? Ferdinando Nicoletti, Italy 4. Vitamin D in Autoimmunity. Ifigania Kostoglou–Athanasidou, Greece 5. RA and type 2 diabetes: the role of the metabolic inflammation. Roberto Giacomelli, Italy 6. Defective lysosomes and lysosomal autophagy in lupus. Sylviane Muller, France</p>	<p>DEBATE 01 Glucocorticoids in the Management of RA Chair: Yehuda Shoenfeld, Israel, Johan Rönnelid, Sweden Yes: Maurizio Cutolo, Italy No: György Nagy, Hungary</p>	<p>PS08 Vasculitis - update Chairs: Gleb Slobodin, Israel; Alojzija Hočevar, Slovenia; Jan Damoiseaux, The Netherlands 1. Innate immunity in ANCA-associated vasculitis. Jan Damoiseaux, The Netherlands 2. CNS vasculitis - update. Gisele Zandman-Goddard, Israel 3. Adult IgA vasculitis. Alojzija Hočevar, Slovenia 4. Polymyalgia rheumatica (PMR) or late onset PMR-like RA - a diagnostic conundrum. Gleb Slobodin, Israel 5. Predictors of remission and flare in patients with polymyalgia rheumatica. Carlo Perricone, Italy 6. Pathways deregulated in giant cell arteritis by gene expression profiling in temporal artery biopsies. Dr.ssa Stefania Croci, Italy</p>
16:45 – 17:15	COFFEE BREAK, EXHIBITION, POSTER VIEWING		
17:15 – 18:30	<p>PANEL DISCUSSION 01. Hippocrates versus ChatGPT Discussants: Howard Amital, Israel and Dimitrios Bogdanos, Greece vs Yoad Dvir, Israel 1) Diagnostic dilemma 2) Therapeutic dilemma 3) HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS: ARTIFICIAL INTELLIGENCE AND ITS ROLE IN AIDING DIAGNOSIS. Antonio Lamas, Portugal</p>	<p>DEBATE 02 What Is the Best Instrument To Measure Disease Activity in SLE? Chair: Andrea Doria, Italy BILAG: Edward Vital, UK SLE-DAS: Luís Inês, Portugal</p>	<p>PS09 Sjögren syndrome and novel therapies in autoimmunity Chairs: Roberto Gerli, Italy; Athanasios Tzioufas, Greece; Piercarlo Sarzi-Puttini, Italy 1. Sjögren's syndrome towards stratified Medicine. Athanasios Tzioufas, Greece 2. Long-term damage evaluation in primary Sjogren's syndrome. Roberto Gerli, Italy 3. Accrual damage in Sjogren Syndrome. Roberto Giacomelli, Italy 4. Mixed connective tissue diseases: classification criteria, clinical presentation and prognosis. Luc Mouthon, France</p>
19:00 – 20:00	Talk with Professor in the Bar		

Sunday, 19 May 2024

	HALL A	HALL B	HALL C
08:00 – 10:00	<p>PLENARY 2 Chairs: Koike Takao, Japan, Saša Čučnik, Slovenia, Dario Roccatello, Italy 1. New paradigms in the management of SLE. Andrea Doria, Italy 2. Why we develop Autoimmune diseases? Yehuda Shoenfeld, Israel 3. Daratumumab monotherapy for refractory lupus nephritis. Dario Roccatello, Italy</p> <p>----- Challenge the Expert Chairs: Yehuda Shoenfeld, Christopher Edwards Experts: Xavier Bossuyt 1. How can reporting of autoantibody test results be improved? 2. Can we reliably measure autoantibodies that recognize conformational epitopes? 3. Can the impact of autoantibodies in diagnostic criteria be upgraded? Pier Luigi Meroni 1. Is the old statement 'one autoantibody/one disease' still satisfactory in 2024? 2. Do the last classification criteria change our routine approach to Anti Phospholipid Syndrome?</p>		
10:00 – 10:30	COFFEE BREAK, EXHIBITION, POSTER VIEWING, New Book signing session 2 (10:05-10:25, Exhibition area) 'Infection and Autoimmunity' Participants: Prof. Yehuda Shoenfeld, Prof. Naim Mahroum		
10:30 – 12:00	<p>PS10 Infections and Autoimmunity Chairs: Carlos Vasconcelos, Portugal; Naim Mahroum, Turkey; Savino Sciascia, Italy 1. Infection and Autoimmunity - concept and history, the pandemic of COVID-19. Naim Mahroum, Turkey 2. Viral-induced networks and their link with the development of "neglected autoimmune diseases". Otávio Marques, Brazil 3. Post infectious syndromes: spectrum and autoimmune mechanisms. Carmen Scheibenbogen, Germany 4. Serious Infections in Autoimmune disease patients: experience of a single center cohort. Carlos Vasconcelos, Portugal 5. The unique combination of gut microbiome and viral infection in FM patients. Zaiga Nora-Krūkle, Latvia 6. Adaptive immunity in COVID-19 – two sides of the coin. Nina Babel, Germany</p>	<p>PS11 Autoimmune Syndrome Induced by Adjuvants (Shoenfeld's Syndrome) Chairs: Jan Willem Cohen Tervaert, Canada; Luis Javier Jara, Mexico; Boris Gilburd, Israel 1. ASIA (Shoenfeld's syndrome) due to implants: a hype or a real phenomenon? Jan Willem Cohen Tervaert, Canada 2. Hyperprolactinemia in ASIA after mineral oil injection and silicone breast implants. Luis Javier Jara, Mexico 3. ASIA and silicone. Gustavo Emilio Schenone, Argentina 4. Tattoo and Autoimmunity. Amir Tanay, Israel 5. Is vaccination in children with immune mediated diseases safe and immunogenic? Natasa Toplak, Slovenia 6. Exploring the exposome's influence on vaccination effectiveness. Pedro Bastos, Sweden</p>	<p>PS12 Autoimmunity in the Central Nervous System Chairs: Ron Milo, Israel; Manuel Martinez-Lavin, Mexico; Miri Blank, Israel 1. Better understanding the underlying mechanism of fibromyalgia syndrome using circulating extracellular vesicles. Gilad Halpert, Israel 2. Fibromyalgia : neuroinflammation or autoimmunity? Piercarlo Sarzi-Puttini, Italy 3. The different clinical manifestations of small fiber neuropathy. Manuel Martinez-Lavin, Mexico 4. New B cell-targeted therapies for multiple sclerosis. Ron Milo, Israel 5. The nervous system in rheumatoid arthritis. Christopher Edwards, UK 6. Immune reconstitution therapy vs chronic immunomodulation or immunosuppression for MS and other neuroimmune diseases. Dimitrios Karusis, Israel</p>
12:00 – 14:00	LUNCH BREAK, EXHIBITION, E-POSTER DISCUSSIONS, E-POSTER VIEWING, New Book signing session 3 (12:10 - 13:10, Exhibition area) 'Adjuvants and Autoimmunity/ASIA Syndrome' Participants: Prof. Yehuda Shoenfeld, Prof. Abdulla Watad	INDUSTRY SUPPORTED SESSION 12:15 - 13:45 NOT INCLUDED IN THE MAIN EVENT CME/CPD CREDIT	
14:00 – 15:30	<p>PS13 Rheumatoid Arthritis and Myositis (Muscles) Chairs: Christopher Edwards, UK; Gleb Slobodin, Israel; Olga Vera-Lastra, Mexico 1. Ways to prevent difficult-to-treat RA. Gleb Slobodin, Israel 2. Efficacy and safety of JAKi for the treatment of RA in real-life. Carlo Perricone, Italy 3. Inflammatory myopathies and ILD. Sonja Praprotnik, Slovenia 4. From fat to muscle- an unusual type of myositis - a case report and literature review. Milena Tocut, Israel 5. Correct nutrition as immunomodulatory co-therapy in rheumatoid arthritis. Maurizio Cutolo, Italy</p>	<p>PS14 Therapeutic Challenges in Autoimmunity Chairs: Martin Aringer, Germany; Gellerman Gary, Israel; Doron Rimar, Israel 1. Helminth derivative to treat autoimmunity. Miri Blank, Israel 2. News on Janus kinase (Jak) function and Jak inhibition in SLE. Martin Aringer, Germany 3. Autologous stem cell transplantation versus upfront combination therapy of rituximab and mycophenolate mofetil for progressive diffuse systemic sclerosis - 2 year outcomes. Doron Rimar, Israel 4. The use of stem cell therapies for Multiple Sclerosis and neuroinflammatory and neurodegenerative diseases. Dimitrios Karusis, Israel 5. Antibody-driven photodynamic and sonodynamic therapies: a look into the future of targeted medicine. Gary Gellerman, Israel 6. Functional consequences of immunological checkpoint inhibitor therapies on lymphocytes. Ulrich Sack, Germany</p>	<p>PS15 EASI Session: The new APS classification criteria: implications in clinical practice 1. Assessment of the clinical domain within the new APS classification criteria. Denis Wahl, France 2. Laboratory classification criteria for APS are not the same as diagnostic laboratory criteria for APS. Katrien Devreese, Belgium 3. The impact of the new APS classification criteria on pregnancy morbidity. Savino Sciascia, Italy 4. Panel discussion</p>
15:30 – 15:45	SHORT BREAK		

15:45 – 16:45	<p>PS16 Big data, Prediction, Monitoring and Prevention Chairs: Gisele Zandman-Goddard, Israel; Matthias Schneider, Germany; Gideon Flusser, Israel 1. Standardized core data sets. Matthias Schneider, Germany 2. Precision medicine in Lupus. Gisele Zandman-Goddard, Israel 3. Predictors of severe autoimmune haemolytic anaemia and severe thrombocytopenia in SLE. Bernardo Pons-Estel, Argentina 4. Autoantibodies and Precision Medicine. Luis E. Andrade, Brazil 5. Abs against the chemokine receptor CXCR3 as predictor for mortality in a population-based study. Hanna Grasshoff, Germany 6. Big Data in psoriasis. Howard Amital, Israel</p>	<p>DEBATE 03 Might Maintenance Therapy Be Discontinued Once Clinical Remission is Achieved in ANCA-Associated Vasculitis Chair: Ricard Cervera, Spain, Piero Ruscitti, Italy No: Speaker TBA Yes: Dario Roccatello, Italy</p>	<p>PS17 Autoantibodies (ABS) - Prediction, Pathogenic and Prevention Chairs: Pier Luigi Meroni, Italy; Michael Mahler, USA; Xavier Bossuyt, Belgium 1. Much more than anti-dsDNA antibodies for lupus nephritis. Pier Luigi Meroni, Italy 2. Portugal Autoimmunity, Immunodeficiency and Autoinflammation in a cohort of patients from a clinical immunology unit. Carlos Vasconcelos, Portugal 3. The stratification of autoimmune patients for personalized therapy: importance of flow cytometry. Christophe Jamin, France 4. Obesity in late adolescence and incidence of Type 1 diabetes in young adulthood. Arnon Afek, Israel</p>
16:45 – 17:15	COFFEE BREAK, EXHIBITION, POSTER VIEWING		
17:15 – 18:30	<p>PANEL DISCUSSION 02 - Difficult cases in Autoimmunity Panel: Carlo Salvarani, Italy, Razzaque Ahmed, USA Presenter and Responder: Carlo Perricone, Italy 1. Case of overlapping EGPA/GPA 2. Case of alopecia universalis which improved at 1 month of treatment with JAK1 inhibitor upadacitinib Presenter and Responder: Ricard Cervera, Spain 3. Case on LUPUS/C-APS Discussion</p>	<p>PS18 Cytokines and Autoimmunity Chairs: Pierre Miossec, France; Luca Cantarini, Italy; Oliver Distler, Switzerland 1. IL-17, 25 years later. Pierre Miossec, France 2. IL-1beta inhibition in Adult onset Still's disease. Luca Cantarini, Italy 3. IL-6, the choroid plexus, and the pathogenesis of neuropsychiatric lupus. Chaim Putterman, Israel 4. The emerging role of macrophage migration inhibitory family of cytokines in autoimmune diseases. From pathogenesis to new treatments? Ferdinando Nicoletti, Italy</p>	<p>PS19 Systemic Autoimmunity, Liver and Gastrointestinal Chairs: Aaron Lerner, Israel, Roberta Gualtierotti, Italy, Zigmund Ehud, Israel 1. Cross-Reactivity and sequence similarity between microbial transglutaminase and human antigens: expanding the exposome of autoimmune diseases. Aaron Lerner, Israel 2. Systemic treatment for alopecia areata. Gasper Markelj, Slovenia</p>
Faculty Dinner			

Monday, 20 May 2024

	HALL A	HALL B	HALL C
08:00 – 10:00	<p>PLENARY 3 Chairs: Angela Tincani, Italy, Christopher Edwards, UK, Arnon Afek, Israel 1. Prediction and prevention of autoimmunity (Using example of Rheumatoid Arthritis, Prediction Models, Review of status of prevention trials). Michael Mahler, USA 2. Abs against the angiotensin receptor type-1 as markers for microvasculopathies in different diseases. Gabriela Riemekasten, Germany 3. Paraneoplastic Autoimmune Laminin-332 Syndrome (PALS). Razzaque Ahmed, USA ----- Challenge the Expert Chairs: Yehuda Shoenfeld, Christopher Edwards Experts: Alessandro Antonelli, Italy 1. Which is the prevalence of systemic autoimmune disorders in patients with autoimmune thyroid diseases, and which is the impact on the health of these patients? 2. Which are the new therapies for Graves' ophthalmopathy, and which is the impact on the disease? 3. Which is the impact of Covid-19 infection in patients with thyroid autoimmunity? Andrea Doria, Italy 1. Why doesn't Interleukin-23 blockade work in Ankylosing Spondylitis 2. What is the difference between Ankylosing Spondylitis and axial Psoriatic Arthritis in terms of pathogenesis 3. Will Faecal microbial transplants revolution Spondyloarthritis and prevention?</p>		
10:00 – 10:30	COFFEE BREAK, EXHIBITION, POSTER VIEWING		
10:30 – 12:00	<p>PS20 Novel Autoimmune Diseases Chairs: Ivica Lazurova, Slovakia; Ora Shovman, Israel; Michael Ehrenfeld, Israel 1. Hypocryoglobulinaemia: a new entity? Dario Roccatallo, Italy 2. Expanding the spectrum of the hyperferritinemic syndrome, from pathogenic mechanisms to clinical observations, and therapeutic implications. Piero Ruscitti, Italy 3. An update on CPPD diagnosis and management. Ora Shovman, Israel 4. What's immune in ankylosing spondylitis? (or difficult cases) Abdulla Watad, Israel 5. Acquired hemophilia: a too often overlooked autoimmune disease. Roberta Gualtierotti, Italy</p>	<p>PS21 Systemic Sclerosis Chairs: Alexandra Balbir-Gurman, Israel; Oliver Distler, Switzerland; Yaniv Sherer, Israel When to start or escalate treatment in SSC-ILD. Oliver Distler, Switzerland</p>	<p>PS22 Novel Approaches to Handle Autoimmune Diseases Chairs: Carlo Salvarani, Italy; Gilad Halpert, Israel 1. Modulation of autoimmune diseases by targeting the Nfr2-HO1-CO pathway. Ferdinando Nicoletti, Italy 2. Acupuncture therapy of Autoimmune diseases – State of the Art. Dorit Gamus, Israel 3. The potential of autologous patient-derived circulating extracellular vesicles to improve drug delivery in inflammatory rheumatic autoimmune diseases. Gilad Halpert, Israel 4. What's new in the treatment of large vessel vasculitis. Carlo Salvarani, Italy di Reggio Emilia e UNIMORE, Italy</p>
12:00 – 14:00	LUNCH BREAK, EXHIBITION, E-POSTER DISCUSSIONS, E-POSTER VIEWING	INDUSTRY SUPPORTED SESSION 12:15 - 13:45 NOT INCLUDED IN THE MAIN EVENT CME/CPD CREDIT	
14:00 – 15:30	<p>PS23 Pediatric and Autoimmunity Chairs: Sefi Uziel, Israel; Tadej Avcin, Slovenia; Angello Ravelli, Italy 1. Next generation: what we know of children born to patients with systemic autoimmune diseases. Angela Tincani, Italy 2. APLA- SLE- TTP- MAS- what is the egg and what is the chicken? Sefi Uziel, Israel 3. Immune interventions in pre- and early- type 1 diabetes. Tadej Battelino, Slovenia 4. Autoimmunity in inborn errors of immunity and clinical approaches. Tadej Avcin, Slovenia 5. Monogenic causes of SLE and related clinical conditions. Alexandre Belot, France 6. Advances in the management of juvenile idiopathic arthritis. Angello Ravelli, Italy</p>	<p>PS24 Mechanisms in Autoimmunity (Part 2) Chairs: Ferdinando Nicoletti, Italy; Marcos López-Hoyos, Spain; Christophe Jamin, France 1. Abstract ID 702 Extracellular vesicles in autoimmunity. Polona Žigon, Slovenia 2. Auto and allo-immunity in solid organ transplantation. Risk for humoral graft rejection. Marcos López-Hoyos, Spain</p>	<p>PS25 Diagnostics in Autoimmunity Chairs: Nicola Bizzaro, Italy; Torsten Matthias, Maria Infantino, Italy 1. EULAR/ACR 2019 SLE classification criteria – lessons learned in the first five years. Martin Aringer, Germany 2. Critical issues in autoantibody tests used as classification criteria for autoimmune diseases. Nicola Bizzaro, Italy 3. Circulating calprotectin: a marker gaining awareness. Maria Infantino, Italy 4. The use of advanced infrared spectroscopy for diagnosis of rheumatic disorders (fibromyalgia and rheumatoid arthritis). Boris Gilburd, Israel</p>
15:30 – 15:45	SHORT BREAK		

15:45 – 16:45	<p>PS26 Pearls in Autoimmunity 2023 Chairs: Amir Tanay, Israel; Otávio Marques, Brazil; Luc Mouthon, France</p> <ol style="list-style-type: none"> COVID-19 vaccine related autoimmune rheumatic diseases. Michael Ehrenfeld, Israel Harnessing the power of AI in medical research & patient treatment. Yoav Dvir, Israel Allergy and Autoimmunity, revisited "through the looking glass". Amir Tanay, Israel Is the syndrome of postural orthostatic tachycardia autoimmune ? (results and review) Zora Lazurova, Slovakia 	<p>PS27 Nutrition and Life Style in Autoimmunity Chairs: Pedro Bastos, Sweden; Vania Borba, Portugal; Carina Benzvi, Israel</p> <ol style="list-style-type: none"> Emerging role of Nutrition in the prevention and treatment of autoimmune diseases and immunosenescence. Vania Borba, Portugal The food additive: microbial transglutaminase is a potential inducer of autoimmune diseases. Aaron Lerner, Israel Lifestyle triggers of neuroinflammation. Pedro Bastos, Sweden 	<p>PS28 Thyroid and Endocrine System Chairs: Alessandro Antonelli, Italy; Ifigania Kostoglou–Athanasassiou, Greece; Roberto Giacomelli, Italy</p> <ol style="list-style-type: none"> Graves' Ophthalmopathy epidemiology, pathogenesis and new therapies. Alessandro Antonelli, Italy Vitamin D levels in Slovak women with autoimmune thyroid disease. Ivica Lazurova, Slovakia Thyroid autoimmunity and COVID-19. Ifigania Kostoglou–Athanasassiou, Greece The potential role of Prolactin in A.S.I.A. Luis Javier Jara, Mexico
16:45 – 17:15	COFFEE BREAK, EXHIBITION, POSTER VIEWING		
17:15 – 18:30	<p>PS29 Pathogenesis of Autoimmune Condition Chairs: Stefania Croci, Italy; Tadej Battelino, Slovenia; Dominique Farge, France</p> <ol style="list-style-type: none"> Hyperferritinemia as a marker of worse outcome in patients with COVID-19 at hospital admission. Gisele Zandman-Goddard, Israel Checkpoint proteins as a gate between autoimmune rheumatic diseases and cancer. Maurizio Cutolo, Italy Update on checkpoint inhibitors induced autoimmunity. Michael Ehrenfeld, Israel Eosinophilic fasciitis: from diagnosis to treatment. Luc Mouthon, France 	<p>PS30 Kidney and Autoimmunity Chairs: Chaim Putterman, Israel; Sylviane Muller, France; Gasper Markelj, Slovenia</p> <ol style="list-style-type: none"> Update on therapy of lupus nephritis with special focus on refractory forms. Dario Roccatello, Italy Long term renal outcome in a cohort of Portuguese Lupus patients. Carlos Vasconcelos, Portugal The CD6/ALCAM pathway as a novel biomarker and treatment target in lupus nephritis. Chaim Putterman, Israel Difficult to treat systemic lupus erythematosus. Marta Mosca, Italy Is Protocol Biopsy Required in Lupus Nephritis? Mariele Gatto, Italy 	<p>PS31 ICAP Session</p>